112 related articles for article (PubMed ID: 38640855)
21. Upregulated LINC01088 facilitates malignant phenotypes and immune escape of colorectal cancer by regulating microRNAs/G3BP1/PD-L1 axis.
Li C; Pan B; Wang X; Liu X; Qin J; Gao T; Sun H; Pan Y; Wang S
J Cancer Res Clin Oncol; 2022 Aug; 148(8):1965-1982. PubMed ID: 35357586
[TBL] [Abstract][Full Text] [Related]
22. eIF5B regulates the expression of PD-L1 in prostate cancer cells by interacting with Wig1.
Li Q; Xiao M; Shi Y; Hu J; Bi T; Wang C; Yan L; Li X
BMC Cancer; 2021 Sep; 21(1):1022. PubMed ID: 34525951
[TBL] [Abstract][Full Text] [Related]
23. Th22 cell accumulation is associated with colorectal cancer development.
Huang YH; Cao YF; Jiang ZY; Zhang S; Gao F
World J Gastroenterol; 2015 Apr; 21(14):4216-24. PubMed ID: 25892871
[TBL] [Abstract][Full Text] [Related]
24. Galangin inhibits programmed cell death-ligand 1 expression by suppressing STAT3 and MYC and enhances T cell tumor-killing activity.
Zhong Y; Li MY; Han L; Tai Y; Cao S; Li J; Zhao H; Wang R; Lv B; Shan Z; Zuo HX; Piao L; Jin HL; Xing Y; Jin X; Ma J
Phytomedicine; 2023 Jul; 116():154877. PubMed ID: 37267692
[TBL] [Abstract][Full Text] [Related]
25. Th17 cells inhibit CD8
Wang D; Yu W; Lian J; Wu Q; Liu S; Yang L; Li F; Huang L; Chen X; Zhang Z; Li A; Liu J; Sun Z; Wang J; Yuan W; Zhang Y
J Hematol Oncol; 2020 Jun; 13(1):68. PubMed ID: 32503584
[TBL] [Abstract][Full Text] [Related]
26. N
Liu Z; Wang T; She Y; Wu K; Gu S; Li L; Dong C; Chen C; Zhou Y
Mol Cancer; 2021 Aug; 20(1):105. PubMed ID: 34416901
[TBL] [Abstract][Full Text] [Related]
27. ACT001 reduces the expression of PD-L1 by inhibiting the phosphorylation of STAT3 in glioblastoma.
Tong L; Li J; Li Q; Wang X; Medikonda R; Zhao T; Li T; Ma H; Yi L; Liu P; Xie Y; Choi J; Yu S; Lin Y; Dong J; Huang Q; Jin X; Lim M; Yang X
Theranostics; 2020; 10(13):5943-5956. PubMed ID: 32483429
[TBL] [Abstract][Full Text] [Related]
28. Fructose-1,6-bisphosphatase loss modulates STAT3-dependent expression of PD-L1 and cancer immunity.
Wang B; Zhou Y; Zhang J; Jin X; Wu H; Huang H
Theranostics; 2020; 10(3):1033-1045. PubMed ID: 31938049
[No Abstract] [Full Text] [Related]
29. Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3.
Zheng B; Ren T; Huang Y; Guo W
Biochem Biophys Res Commun; 2018 Jan; 495(2):1695-1701. PubMed ID: 29225166
[TBL] [Abstract][Full Text] [Related]
30. Uncovering the colorectal cancer immunotherapeutic potential: Evening primrose (Oenothera biennis) root extract and its active compound oenothein B targeting the PD-1/PD-L1 blockade.
Lee EJ; Kim YS; Kim JH; Woo KW; Park YH; Ha JH; Li W; Kim TI; An BK; Cho HW; Han JH; Choi JG; Chung HS
Phytomedicine; 2024 Mar; 125():155370. PubMed ID: 38266440
[TBL] [Abstract][Full Text] [Related]
31. Polo-like kinase 3 inhibits glucose metabolism in colorectal cancer by targeting HSP90/STAT3/HK2 signaling.
Ou B; Sun H; Zhao J; Xu Z; Liu Y; Feng H; Peng Z
J Exp Clin Cancer Res; 2019 Oct; 38(1):426. PubMed ID: 31655629
[TBL] [Abstract][Full Text] [Related]
32. High baseline tumor burden-associated macrophages promote an immunosuppressive microenvironment and reduce the efficacy of immune checkpoint inhibitors through the IGFBP2-STAT3-PD-L1 pathway.
Wen Z; Sun H; Zhang Z; Zheng Y; Zheng S; Bin J; Liao Y; Shi M; Zhou R; Liao W
Cancer Commun (Lond); 2023 May; 43(5):562-581. PubMed ID: 37031362
[TBL] [Abstract][Full Text] [Related]
33. Aldehyde Dehydrogenase 2 Mediates Alcohol-Induced Colorectal Cancer Immune Escape through Stabilizing PD-L1 Expression.
Zhang H; Xia Y; Wang F; Luo M; Yang K; Liang S; An S; Wu S; Yang C; Chen D; Xu M; Cai M; To KKW; Fu L
Adv Sci (Weinh); 2021 May; 8(10):2003404. PubMed ID: 34026438
[TBL] [Abstract][Full Text] [Related]
34. Gracillin shows potent efficacy against colorectal cancer through inhibiting the STAT3 pathway.
Yang L; Zhu T; Ye H; Shen Y; Li Z; Chen L; Wang C; Chen X; Zhao H; Xiang Y; Xiao Z; Zhao C; Li J; Hu W
J Cell Mol Med; 2021 Jan; 25(2):801-812. PubMed ID: 33259114
[TBL] [Abstract][Full Text] [Related]
35. Neddylation inhibition upregulates PD-L1 expression and enhances the efficacy of immune checkpoint blockade in glioblastoma.
Zhou S; Zhao X; Yang Z; Yang R; Chen C; Zhao K; Wang W; Ma Y; Zhang Q; Wang X
Int J Cancer; 2019 Aug; 145(3):763-774. PubMed ID: 31044422
[TBL] [Abstract][Full Text] [Related]
36. Fraxinellone has anticancer activity in vivo by inhibiting programmed cell death-ligand 1 expression by reducing hypoxia-inducible factor-1α and STAT3.
Xing Y; Mi C; Wang Z; Zhang ZH; Li MY; Zuo HX; Wang JY; Jin X; Ma J
Pharmacol Res; 2018 Sep; 135():166-180. PubMed ID: 30103001
[TBL] [Abstract][Full Text] [Related]
37. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
38. PER2 binding to HSP90 enhances immune response against oral squamous cell carcinoma by inhibiting IKK/NF-κB pathway and PD-L1 expression.
Zhang Z; Sun D; Tang H; Ren J; Yin S; Yang K
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37914384
[TBL] [Abstract][Full Text] [Related]
39. TMEM160 promotes tumor immune evasion and radiotherapy resistance via PD-L1 binding in colorectal cancer.
Dai X; Wu Z; Ruan R; Chen J; Huang C; Lei W; Yao Y; Li L; Tang X; Xiong J; Feng M; Deng J
Cell Commun Signal; 2024 Mar; 22(1):168. PubMed ID: 38454413
[TBL] [Abstract][Full Text] [Related]
40. BATF3 promotes malignant phenotype of colorectal cancer through the S1PR1/p-STAT3/miR-155-3p/WDR82 axis.
Li P; Weng Z; Li P; Hu F; Zhang Y; Guo Z; Shen W; Zhao C; Dai S
Cancer Gene Ther; 2021 May; 28(5):400-412. PubMed ID: 33057139
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
